trending Market Intelligence /marketintelligence/en/news-insights/trending/sawkkrqgfdaxtkmpfr2zwg2 content esgSubNav
In This List

Akcea Therapeutics adds PhRMA exec to board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Akcea Therapeutics adds PhRMA exec to board

Akcea Therapeutics Inc. appointed Richard Moscicki to the Cambridge, Mass.-based biopharmaceutical company's board.

Moscicki is the executive vice president for science and regulatory advocacy and the chief medical officer at Pharmaceutical Research and Manufacturers of America, a trade group representing companies in the pharmaceutical industry in the U.S.

He is also the former deputy center director for science operations for the U.S. Food and Drug Administration's Center for Drug Evaluation and Research.

Moscicki is expected to help the company, an affiliate of Ionis Pharmaceuticals Inc., as it prepares for two rare disease drug launches under regulatory review in the U.S., Canada and the EU.